Paclitaxel in the treatment of patients with anglosarcoma of the scalp or face

Cancer

Volumn 86, Issue 10, 1999, Pages 2034-2037

  Fata, Farid ^a   O'Reilly, Eileen ^a   Ilson, David ^a   Pfister, David ^a   Leffel, David ^b   Kelsen, David P ^a   Schwartz, Gary K ^a   Casper, Ephraim S ^a,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Mem Sloan Kettering at St Clare's ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADULT; AGED; ANGIOSARCOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CLINICAL ARTICLE; FACE; FEMALE; HUMAN; MALE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SCALP;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FACIAL NEOPLASMS; FEMALE; HEMANGIOSARCOMA; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; SCALP; SKIN NEOPLASMS;

EID: 0033571557     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.0.CO;2-P     Document Type: Article

References (18)

1. Holden CA, Spittle MF, Jones EW. Angiosarcomas of the face and scalp: prognosis and treatment. Cancer 1987;59:1046-57.
2. Nanus DM, Kelsen D, Clark DG. Radiation-induced angiosarcoma. Cancer 1987;60:777-9.
3. Mark R, Poen J, Tran L, Fu Y, Juillard G. Angiosarcoma: a report of 67 patients and a review of the literature. Cancer 1996;77:2400-6.
4. Casper ES, Waltzman R, Schwanz G, Sugarman A, Pfister D, Ilson D. Phase II study of paclitaxel in sarcoma. Cancer Invest 1998;16:442-6.
5. William L, Shaha A, Shah J. Angiosarcoma of the head and neck. Am J Surg 1994;168:451-4.
6. Morrison W, Byers R, Garden A, Evans H, Ang K, Peters L. Cutaneous angiosarcoma of the head and neck: a therapeutic dilemma. Cancer 1995;76:319-27.
7. Belotti D, Vergani V, Drudis T. The microtubule-affecting drug paclitaxel has anti-angiogenic activity. Clin Cancer Res 1996;2:1843-9.
8. Klauber N, Parangi S, Flynn E, D'Amato J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57: 81-6.
9. Welles L, Saville W, Lietzau J, Pluda J, Wyvill M, Feuerstein I. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 1998;16:1112-21.
10. Ensoli B, Morris B, Gendelman R. Cytokine-mediated activation of Bcl-2 expression in Kaposi's sarcoma (KS) and synergy by HIV-1 Tat protein: role in progression of AIDS-KS. J AIDS Hum Retroviral, Abstracts of the Annual Meeting of the Institute of Human Virology, Baltimore, MD, September 7-13, 1996: p. 22.
11. Haldar S, Chintapalli J, Croce C. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996;56:1253-5.
12. Orchard GE, Zeiger B, Jones E, Jones R. An immunocyto-chemical assessment of 19 cases of cutaneous angiosarcoma. Histopathology 1996;28:235-40.
13. Balcerzak S, Benedetti J, Weiss G, Natale R. A Phase II trial of paclitaxel in patients with advanced soft tissue sarcomas: a SWOG study. Cancer 1995;76:2248-52.
14. Patel S, Linke K, Burgess A, Papadopoulos N, Plager C, Jenkins J, et al. Phase II study of paclitaxel in patients with soft tissue sarcomas. Sarcoma 1997;1:95-7.
15. Van Hoesel Q, Verweij J, Catimel G, Clavel M, Kerbrat P, Oosterom A. Phase II study with docetaxel in advanced soft tissue sarcomas of the adult. Ann Oncol 1994;5:539-42.
16. Verweij J, Judson I, Crowther D, Ruka W, Buesa J, Coleman R, et al. Randomized study comparing docetaxel (Taxotere) (T) to doxorubicin (D) in previously untreated soft tissue sarcomas (STS). Proc Am Soc Clin Oncol 1997;16:A1788.
17. Edmonson J, Ebbert L, Nascimento A, Jung S, Mc Graw H, Gerstner J. Phase II study of docetaxel in advanced soft tissue sarcomas. Am J Clin Oncol 1996;19:574-6.
18. Fidias P, Demetri G, Harmon D. Navelbine shows activity in previously treated sarcoma patients: Phase II results from MGH/Dana-Farber/Partner's Cancer Care Study. Proc Am Soc Clin Oncol 1998;17:1977.